ROYALTY PHARMA PLC

Royalty Pharma’s dual Rule 144 sales and $100 m royalty deal with Zealand Pharma show a balanced, long‑term strategy for liquidity and high‑potential life‑science assets.

Royalty Pharma insider trades reveal confidence in stable royalty‑based funding that supports healthcare delivery, R&D, and value‑based contracting.

Royalty Pharma’s May 2026 insider sales and 13F‑NT filing show routine liquidity moves and continued transparency, offering investors insight into executive confidence and portfolio strategy in the pharma sector.

Royalty Pharma plc’s former officers will sell 100,462 shares under a pre‑approved selling plan, with Goldman Sachs handling the compliant Rule 144 transaction.

Royalty Pharma expands into Asia and secures a $250 M royalty‑backed note with Zymeworks to fund late‑stage antibody trials, boosting growth while preserving equity.

Royalty Pharma’s new Asia focus and high‑risk Zymeworks royalty‑loan reveal both growth upside and regulatory risk—an insider look at the firm’s strategic pivot.

Royalty Pharma’s short‑interest fell 50% in February, easing bearish pressure while the company gears up for a TD Cowen fireside chat to discuss strategy, reimbursement, and growth.

Royalty Pharma reports a 12.4 % jump in Q4 2025 net income to US$1.15 billion, driven by higher royalty income and lower expenses, while outlining FX‑hedging plans to safeguard FY‑2026 earnings.

Royalty Pharma reports strong Q4 2025 earnings near $210 M, driven by stable royalty portfolio and disciplined capital use, while FX risk shapes 2026 outlook.

Royalty Pharma’s $500 m partnership with Teva to fund TEV‑408—an anti‑IL‑15 antibody—could unlock high‑potential autoimmune therapies and boost RPL’s value while managing risk.